Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • Thursday
Zealand Pharma slides as concerns over patients quitting survodutide trials resurfaceReuters • 10/01/26
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/13/26
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmakerCNBC • 06/19/26
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trialMarket Watch • 06/08/26
Zealand Pharma A/S (ZLDPF) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/26
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumblingMarket Watch • 03/06/26
Zealand Pharma slump wipes billions off its value after obesity drug data disappointsReuters • 03/06/26
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity TranscriptSeeking Alpha • 03/06/26
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 6.8% Jump Turn into More Strength?Zacks Investment Research • 01/23/26
Zealand Pharma A/S (ZLDPF) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26